AbCellera Biologics (ABCL) Receives a Buy from Stifel Nicolaus
In a report released today, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on AbCellera Biologics, with a price target of $7.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Willey is a 4-star analyst with an average return of 6.8% and a 42.39% success rate. Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Exelixis, and Insmed.
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $7.00.
Based on AbCellera Biologics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $8.96 million and a GAAP net loss of $57.12 million. In comparison, last year the company earned a revenue of $6.51 million and had a GAAP net loss of $51.11 million
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.